🇺🇸 FDA
Patent

US 12053531

Materials and methods for treatment of Duchenne Muscular Dystrophy

granted A61KA61K35/28A61K35/34

Quick answer

US patent 12053531 (Materials and methods for treatment of Duchenne Muscular Dystrophy) held by Vertex Pharmaceuticals Incorporated expires Mon Aug 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Vertex Pharmaceuticals Incorporated
Grant date
Tue Aug 06 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
5
CPC classes
A61K, A61K35/28, A61K35/34, A61K38/465, A61K48/005